Consensus estimates for Icecure Medical's Q2 2026 performance project revenue of approximately $1.45 million and an adjusted loss of -$1.52 per share, with the stock's current price of $3.13 trailing the average analyst target of $30.50.
Investors are primarily focused on the commercial trajectory of the ProSense cryoablation system in the United States, which serves as the company's core growth engine following FDA authorization in late 2025.
Management recently highlighted a 70% jump in the U.S. active install base, reflecting accelerating physician demand across major metropolitan hospitals.
The market is also awaiting updates on the enrollment of the "ChoICE" post-marketing clinical study and a potential inclusion in NCCN guidelines, both of which are pivotal for securing widespread insurance reimbursement and driving long-term adoption.